Acceptance Rate and Reasons for Rejection of Long Acting Injectable Antiretrovirals
Authors:
- 28 December 2022
- journal article
- research article
- Published by Springer Nature in AIDS and Behavior
- Vol. 27 (7) , 2370-2375
Abstract
In January 2021, cabotegravir/rilpivirine, the first extended-release injectable regimen for the treatment of Human Immunodeficiency Virus (HIV) was approved. Long-acting injections have the potential to improve adherence and viral suppression. We analyzed the acceptance rate of, and reasons for declining to switch to, the new regimen. During routine appointments, 102 people living with HIV (PLWH) were presented with information on the new medication and asked if they would like to switch from their current regimen. If they declined to switch, they were asked why. Sixty-nine percent of respondents declined to switch, with frequency of injections as the primary reason. Patients indicated they would be willing to switch if the interval between injections was longer. Forty percent of the patients accepting the injectable anti-retrovirals (ARVs) were not on any other medications. Barriers to switching to long-acting injectable ARVs include the need for more frequent provider visits, aversion to needles, and a perceived lack of evidence supporting the new medication.Keywords
This publication has 20 references indexed in Scilit:
- Will Gay and Bisexual Men Taking Oral Pre-exposure Prophylaxis (PrEP) Switch to Long-Acting Injectable PrEP Should It Become Available?AIDS and Behavior, 2017
- Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort StudiesSchizophrenia Bulletin, 2017
- Barriers to HIV Medication Adherence as a Function of Regimen SimplificationAnnals of Behavioral Medicine, 2016
- Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral TherapyJAMA, 2016
- Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysisBMC Medicine, 2014
- The Demand for Antiretroviral Drugs in the Illicit Marketplace: Implications for HIV Disease Management Among Vulnerable PopulationsAIDS and Behavior, 2014
- Long-Acting Parenteral Nanoformulated Antiretroviral Therapy: Interest and Attitudes of HIV-Infected PatientsNanomedicine, 2013
- Antiretroviral Medication Diversion Among HIV-Positive Substance Abusers in South FloridaAmerican Journal of Public Health, 2013
- Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled studyJournal of Bone and Mineral Research, 2010
- Fixed-Dose Combinations Improve Medication Compliance: A Meta-AnalysisThe American Journal of Medicine, 2007